The third limitation is that AD-related CSF biomarkers, including Aβ, T-tau, p-tau181, and GFAP, were not examined in this study for cross comparison; AD-related PET/CT and α-syn-related PET/CT should be considered in future studies. The gene discussed is MAPT; the disease is Alzheimer disease.